ArticleJournal of the National Cancer Institute2013
Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.
Article in Journal of the National Cancer Institute, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.European urology · 2023Pooled it
- PSCA rs2294008 Polymorphism with Increased Risk of Cancer.PloS one · 2015Pooled it
- The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer.Journal of advanced research · 2025Review
- Significance of PSCA as a novel prognostic marker and therapeutic target for cancer.Cancer cell international · 2024Review
- Mediation by differential DNA methylation of known associations between single nucleotide polymorphisms and bladder cancer risk.BMC medical genetics · 2020Article
- Identification and replication of the interplay of four genetic high-risk variants for urinary bladder cancer.Carcinogenesis · 2017Article
- Association of high-evidence gastric cancer susceptibility loci and somatic gene expression levels with survival.Carcinogenesis · 2017Article
- A Multiple Interaction Analysis Reveals ADRB3 as a Potential Candidate for Gallbladder Cancer Predisposition via a Complex Interaction with Other Candidate Gene Variations.International journal of molecular sciences · 2015Article
- Association between PSCA mRNA expression levels and rs2294008 polymorphism in transitional cell cancer of the bladder.Oncology letters · 2015Article
- Prostate stem cell antigen variation rs2294008 associated with the risk of bladder cancer.International journal of clinical and experimental medicine · 2015Article
- DNA methylation levels at chromosome 8q24 in peripheral blood are associated with 8q24 cancer susceptibility loci.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease.Cancer research · 2014Article
- Targeted therapies in urothelial carcinoma.Current opinion in oncology · 2014Review
- Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?International journal of molecular sciences · 2013Review
- Impact of PSCA variation on gastric ulcer susceptibility.PloS one · 2013Article
- Targeting molecular aberrations in urothelial carcinoma: are we almost there?American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2013Review
- Dysregulation of mRNA splicing in urothelial carcinoma: Clinical, diagnostic and therapeutic implications.Bladder cancer (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 1 country.
Funding
Abstract
A monoclonal antibody against prostate stem cell antigen (PSCA) has emerged as a novel cancer therapy currently being tested in clinical trials for prostate and pancreatic cancers, but this treatment is likely to be efficient only in patients with PSCA-expressing tumors. The present study demonstrates that a genetic variant (rs2294008) discovered by bladder cancer genome-wide association studies is a strong predictor of PSCA protein expression in bladder tumors, as measured by two-sided multivariable linear regression (P = 6.46×10(-11); n = 278). The association pattern is similar in non-muscle-invasive tumors, stages Ta (P = 3.10×10(-5); n = 173) and T1 (P = 2.64×10(-5); n = 60), and muscle-invasive tumors, stages T2 (P =.01; n = 23) and T3/4 (P =.03; n = 22). The study suggests that anti-PSCA immunotherapy might be beneficial for bladder cancer patients with high tumor PSCA expression, which is statistically significantly associated with the presence of CT and TT genotypes of a common genetic variant, rs2294008. Future clinical studies will be needed to validate PSCA as a therapeutic target for bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.